AFINITOR
Total Payments
$133.6M
Transactions
26,958
Doctors
7,295
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.4M | 15 | 7 |
| 2023 | $2.2M | 14 | 3 |
| 2022 | $2.7M | 37 | 19 |
| 2021 | $4.2M | 662 | 487 |
| 2020 | $12.8M | 618 | 407 |
| 2019 | $24.7M | 2,304 | 1,383 |
| 2018 | $32.1M | 9,078 | 3,757 |
| 2017 | $53.5M | 14,230 | 4,901 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $132.4M | 722 | 99.1% |
| Food and Beverage | $423,256 | 25,551 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $291,638 | 102 | 0.2% |
| Travel and Lodging | $183,311 | 360 | 0.1% |
| Consulting Fee | $158,089 | 48 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $91,225 | 96 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $69,904 | 23 | 0.1% |
| Education | $867.56 | 56 | 0.0% |
Payments by Type
Research
$132.4M
722 transactions
General
$1.2M
26,236 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A THREE ARM RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF TWO TEOUGH RANGES OF EVEROLIMUS AS ADJUNCTIVE THERAPY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX TSC WHO HAVE REFRACTORY PARTIAL ONSET SEIZURES | Novartis Pharmaceuticals Corporation | $15.3M | 0 |
| PHASE II TRIAL OF LONAFARNIB PRAVASTATIN ZOLEDRONATE AND EVEROLIMUS IN PROGERIA | Novartis Pharmaceuticals Corporation | $13.8M | 0 |
| EVALUATING THE SAFETY AND EFFICACY OF EVEROLIMUS IN THE TREATMENT OF NEUROCOGNITIVE AND SOCIAL DEFICITS IN PATIENTS WITH PTEN MUTATION | Novartis Pharmaceuticals Corporation | $11.4M | 0 |
| TRIAL OF EVEROLIMUS RAD001 IN CHILDREN WITH RECURRENT LOW GRADE GLIOMAS | Novartis Pharmaceuticals Corporation | $10.6M | 0 |
| RANDOMIZED PHASE II STUDY OF SORAFENIB AND OR EVEROLIMUS IN PATIENTS WITH RADIOACTIVE IODINE REFRACTORY HURTHLE CELL THYROID CANCER | Novartis Pharmaceuticals Corporation | $8.8M | 0 |
| RANDOMIZED PHASE II STUDY OF MIRACLE MOUTH WASH PLUS HYDROCORTISONE VERSUS PREDNISOLONE MOUTH RINSE TO PREVENT EVEROLIMUS ASSOCIATED STOMATITIS IN POSTMENOPAUSAL WOMEN WITH METATASTIC BREAST CANCER MBC | Novartis Pharmaceuticals Corporation | $6.8M | 0 |
| AN OPEN LABEL PHASE II SINGLE ARM STUDY OF EVEROLIMUS IN COMBINATION WITH LETROZOLE IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC OR LOCALLY ADVANCED BREAST CANCER | Novartis Pharmaceuticals Corporation | $5.4M | 0 |
| A PHASE II PILOT TRIAL OF HYDROXYCHLOROQUINE EVEROLIMUS OR THE COMBINATION FOR PREVENTION OF RECURRENT BREAST CANCER | Novartis Pharmaceuticals Corporation | $4.7M | 0 |
| PHASE II STUDY OF THE LEVONORGESTREL INTRAUTERINE DEVICE ALONE OR IN COMBINATION WITH THE MTORC1 INHIBITOR EVEROLIMUS FOR THE TREATMENT OF STAGE IA GRADE 1 ENDOMETRIOID ENDOMETRIAL CANCER | Novartis Pharmaceuticals Corporation | $3.8M | 0 |
| ENZALUTAMIDE MDV3100 PLUS EVEROLIMUS IN MEN WITH METASTATIC PROSTATE CANCER AND PREVIOUS TREATMENT WITH DOCETAXEL A PHASE I STUDY WITH AN MTD EXPANSION COHORT | Novartis Pharmaceuticals Corporation | $3.3M | 0 |
| FULVESTRANT ALONE VS FULVESTRANT AND EVEROLIMUS VS FULVESTRANT EVEROLIMUS AND ANASTROZOLE A PHASE III RANDOMIZED PLACEBO CONTROLLED TRIAL IN PATIENTS WITH HORMONE RECEPTOR POSITIVE POSTMENOPAUSAL STAGE IV BREAST CANCER | Novartis Pharmaceuticals Corporation | $3.3M | 0 |
| COMBINATION TREATMENT WITH EVEROLIMUS LETROZOLE AND TRASTUZUMAB IN HORMONE RECEPTOR AND HER2 AND OR NEU POSITIVE PATIENTS WITH ADVANCED METASTATIC BREAST CANCER AND OTHER SOLID TUMORS EVALUATING SYNERGY AND OVERCOMING RESISTANCE | Novartis Pharmaceuticals Corporation | $3.0M | 0 |
| AN OPEN LABEL MULTI CENTER EVEROLIMUS ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED EVEROLIMUS STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED EVEROLIMUS TREATMENT | Novartis Pharmaceuticals Corporation | $2.8M | 0 |
| RANDOMIZED PHASE II COMPARISON OF SINGLE AGE CARBOPLATIN VS THE COMBINATION OF CARBOPLATIN AND EVEROLIMUS FOR THE TREATMENT OF ADVANCED TRIPLE NEGATIVE BREAST CANCER | Novartis Pharmaceuticals Corporation | $2.4M | 0 |
| PI3K MTOR PATHWAY ACTIVATION STRATIFIED PHASE II STUDY OF EVEROLIMUS AFINITOR RAD001 WITH AND WITHOUT TEMOZOLOMIDE TEMODAR IN THE TREATMENT OF ADULT PATIENTS WITH SUPRATENTORIAL LOW GRADE GLIOMA | Novartis Pharmaceuticals Corporation | $2.1M | 0 |
| PHASE II STUDY EVALUATING THE COMBINATION OF RAD001 AND SORAFENIB IN THE TREATMENT OF RADIOACTIVE IODINE REFRACTORY THYROID CANCER | Novartis Pharmaceuticals Corporation | $1.9M | 0 |
| Phase II study of the levonorgestrel intrauterine device alone or in combination with the mTORC1 inhibitor everolimus for the treatment of stage Ia grade 1 endometrioid endometrial cancer | Novartis Pharmaceuticals Corporation | $1.8M | 0 |
| ADJUVANT EVEROLIMUS FOR HIGH RISK HORMONE RECEPTOR POSITIVE AND HER2 NEGATIVE BREAST CANCER AS A SUB STUDY OF RXPONDER S1007 A PHASE III RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY PLUS OR MINUS CHEMOTHERAPY IN PATIENTS WITH 1 TO 3 POSITIVE NODES HORMONE RESPONSIVE AND HER2 NEGATIVE BREAST CANCER WITH RECURRENCE SCORE RS OF 25 OR LESS | Novartis Pharmaceuticals Corporation | $1.6M | 0 |
| EVEROLIMUS FOR TSC1 AND OR TSC2 MUTANT CANCER | Novartis Pharmaceuticals Corporation | $1.6M | 0 |
| AFINITOR AND LETROZOLE IN THE TREATMENT OF WOMEN WITH ESTROGEN RECEPTOR POSITIVE OVARIAN AND ENDOMETRIAL CANCER | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
Top Doctors Receiving Payments for AFINITOR
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orange, CA | $132.3M | 716 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Houston, TX | $130,891 | 169 |
| , MD | Internal Medicine | Stony Brook, NY | $59,977 | 48 |
| , M.D | Hematology & Oncology | Durham, NC | $52,430 | 47 |
| , MD | Neurodevelopmental Disabilities | Memphis, TN | $43,535 | 5 |
| , MD | Neurology with Special Qualifications in Child Neurology | Cincinnati, OH | $37,394 | 34 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Cincinnati, OH | $35,555 | 30 |
| , MD | Pediatric Nephrology | Memphis, TN | $28,807 | 14 |
| , MD | Pediatrics | Syracuse, NY | $27,021 | 34 |
| , MD, MPH | Internal Medicine | West Hollywood, CA | $25,846 | 14 |
| , M.D | Hematology | Baltimore, MD | $23,910 | 31 |
| , M.D | Surgical Oncology | Denver, CO | $23,132 | 36 |
| , MD | Surgery | Portland, OR | $20,535 | 8 |
| Dialecti Voudouris | Specialist | New York, NY | $17,754 | 27 |
| , MD | Hematology & Oncology | Rochester, NY | $17,439 | 16 |
| , MD | Medical Oncology | Chicago, IL | $17,276 | 8 |
| , M.D | Neuropathology | Boston, MA | $17,193 | 10 |
| , M.D | Medical Oncology | Houston, TX | $14,316 | 11 |
| , MD | Medical Oncology | Saint Louis, MO | $12,904 | 10 |
| , MD, PHD | Internal Medicine | Albuquerque, NM | $11,826 | 7 |
| , MD | Medical Oncology | Tampa, FL | $10,565 | 7 |
| , M.D | Neurodevelopmental Disabilities | N White Plains, NY | $10,112 | 30 |
| , M.D | Neurodevelopmental Disabilities | Los Angeles, CA | $10,048 | 5 |
| , MD | Medical Oncology | Buffalo, NY | $9,502 | 2 |
| , MD | Hematology & Oncology | Orlando, FL | $9,022 | 9 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $133.4M
- NOVARTIS PHARMACEUTICALS CORPORATION $266,213
Product Information
- Type Drug
- Total Payments $133.6M
- Total Doctors 7,295
- Transactions 26,958
About AFINITOR
AFINITOR is a drug associated with $133.6M in payments to 7,295 healthcare providers, recorded across 26,958 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $1.4M was paid across 15 transactions to 7 doctors.
The most common payment nature for AFINITOR is "Unspecified" ($132.4M, 99.1% of total).
AFINITOR is associated with 20 research studies, including "A THREE ARM RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF TWO TEOUGH RANGES OF EVEROLIMUS AS ADJUNCTIVE THERAPY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX TSC WHO HAVE REFRACTORY PARTIAL ONSET SEIZURES" ($15.3M).